Vibegron is a selective β-3 adrenergic receptor agonist that was first approved for marketing in the United States in 2020. As an innovative drug for the treatment of overactive bladder (OAB), it provides a new treatment option for patients.
How Effective is Vibegron in Treatment?
Core Efficacy Performance
By selectively activating β-3 adrenergic receptors in the bladder, Vibegron effectively relaxes the detrusor muscle and increases bladder capacity, thereby improving a series of symptoms of overactive bladder.
Clinical studies have confirmed that this drug can significantly reduce the patient's daily urination frequency, the number of urge urinary incontinence episodes, and the frequency of urgency episodes.
Characteristics of Symptom Improvement
Patients treated with Vibegron show significant improvements in urination frequency, urge urinary incontinence, and urgency symptoms.
The drug takes effect relatively quickly, and the therapeutic effect can be maintained for a long time.
It is worth noting that Vibegron can not only reduce the frequency of symptoms but also increase the urine volume per urination, which is of great significance for improving the patient's quality of life.
Vibegron Use in Special Populations
Elderly Patients
Vibegron can be used in elderly patients aged 65 years and above. Clinical studies have shown that age does not affect its efficacy.
However, caution and close observation are still required when using it in elderly patients over 75 years old.
Patients with Hepatic or Renal Impairment
Patients with mild to moderate hepatic or renal impairment do not need dose adjustment.
Vibegron is not recommended for patients with severe renal impairment (eGFR < 15 mL/min/1.73 m²) or severe hepatic impairment (Child-Pugh Class C).
Pregnant and Lactating Women
There is currently a lack of data on the use of Vibegron in pregnant women. It can only be considered when the potential benefits outweigh the risks.
Lactating women should weigh the pros and cons and consider suspending breastfeeding or discontinuing the drug.
Pediatric Patients
The efficacy of Vibegron in children under 18 years of age has not been established, and its use is not recommended.
Contraindicated Populations
Vibegron is contraindicated in patients with a known allergy to Vibegron or any component in its formulation.
Before use, the patient's allergy history should be carefully inquired to avoid the occurrence of severe allergic reactions.
Medication Monitoring for Vibegron
Pre-Medication Assessment
Before starting Vibegron treatment, the doctor should conduct a comprehensive assessment of the patient's medical history and medication use, with special attention to the following points:
Whether there is bladder outlet obstruction or other diseases that cause dysuria.
Whether other OAB treatment drugs (especially anticholinergic drugs) are used simultaneously.
Whether drugs that require blood concentration monitoring (such as digoxin) are used.
The basic status of liver and kidney function.
Monitoring for Urinary Retention
Vibegron may increase the risk of urinary retention, especially in patients with bladder outlet obstruction or those using anticholinergic drugs at the same time.
The patient's urination status should be closely observed. If symptoms such as dysuria and weakened urine flow occur, timely evaluation should be conducted and consideration should be given to discontinuing the drug.
Monitoring of Digoxin Blood Concentration
Vibegron can slightly increase the blood concentration of digoxin.
When used in combination, the blood concentration of digoxin should be monitored before starting Vibegron treatment, during treatment, and after drug withdrawal, and the dose of digoxin should be adjusted according to the clinical effect.
